Epidemiology and costs of chronic obstructive pulmonary disease

By K. Chapman, David M. Mannino, J. Soriano, P. Vermeire, A. Buist, M. Thun, C. Connell, A. Jemal, Todd A. Lee, M. Miravitlles and 2 more. European Respiratory Journal, 2006

768 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1c7046ace1ce2902aaf01699f273d33105022e05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. J. Wedzicha
2. T. Seemungal
3. D. Parums
4. P. Barnes
5. P. Calverley

In Pulmonary and Respiratory Medicine

1. D. Parums
2. P. Barnes
3. J. Wedzicha
4. P. Calverley
5. T. Seemungal
6. A. Anzueto
7. Bartolome Celli
8. Jorgen Vestbo

Citations in the corpus

• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. (2008, background): “Neoplasms benign, malignant, and unspecified 18 (3) 15 (2)”
• Oxidative stress, aging, and diseases (2018, neutral): “COPD is a major cause of morbidity and mortality worldwide(39) and its prevalence increases with age.(40) Several • • • • • • •”
• Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities (2009, background): “The prevalence of chronic obstructive pulmonary disease (COPD) varies from country to country, mainly due to the effects of cumulative exposure to smoking and the increased life span of the population. There are increasingly more data on the prevalence and distribution of COPD from around the world,”
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “Costs per patient will vary across countries because these costs depend on how health care is provided and paid (24).”
• Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. (2008, background): “Chronic obstructive pulmonary disease (COPD), a major cause of morbidity worldwide ( 1 ), is characterized by airflow obstruction, as determined by the ratio of the forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).”